Market Research Logo

Warts - Pipeline Review, H2 2015

Warts - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Warts - Pipeline Review, H2 2015’, provides an overview of the Warts’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Warts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Warts and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Warts
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Warts and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Warts products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Warts pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Warts
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Warts pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Warts Overview
Therapeutics Development
Pipeline Products for Warts - Overview
Pipeline Products for Warts - Comparative Analysis
Warts - Therapeutics under Development by Companies
Warts - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Warts - Products under Development by Companies
Warts - Companies Involved in Therapeutics Development
3M Drug Delivery Systems
Agilvax, Inc.
Biogenomics Limited
BioMAS Ltd.
Biota Pharmaceuticals, Inc.
EpiPharm AG
Foamix Pharmaceuticals Ltd.
G&E Herbal Biotechnology Co., Ltd.
Helix BioPharma Corp.
LEO Pharma A/S
MediGene AG
NanoViricides, Inc.
Nielsen Biosciences, Inc.
Novan, Inc.
Novartis AG
Promius Pharma, LLC
RXi Pharmaceuticals Corporation
Tamir Biotechnology, Inc.
Zydus Cadila Healthcare Limited
Warts - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(digoxin + furosemide) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
854-A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
A-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AP-611074 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AS-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AX-03 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Candida Albicans Antigen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DFD-05 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphencyprone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EPI-N06 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HerpeCide-I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
human papilloma virus [strains 6,11] (bivalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
imiquimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ingenol mebutate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon alfa-2b (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon alpha-2b (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LFX-453 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVN-1000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PP-210 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ranpirnase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SB-206 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sinecatechins - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Cervical Cancer and Genital Warts - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Warts - Recent Pipeline Updates
Warts - Dormant Projects
Warts - Discontinued Products
Warts - Product Development Milestones
Featured News & Press Releases
Feb 20, 2015: Medigene receives positive decision on marketing authorisation for Veregen in 8 additional European countries
Sep 30, 2014: Veregen Marketing Authorization Process initiated for eight additional European countries
Jul 16, 2014: Paladin Labs Announces the Canadian Launch of Veregen
Jun 12, 2014: Medigene announces market launch of Veregen in Belgium, Denmark and Finland
Apr 08, 2014: Medigene and Kora Healthcare sign agreement for the commercialisation of Veregen® in United Kingdom and Ireland
Dec 18, 2013: Medigene's drug Veregen launched in Norway and Sweden
Dec 18, 2013: Medigene's drug Veregen launched in Norway and Sweden
Dec 11, 2013: Medigene announces Veregen to be launched in the Czech Republic, Poland, Hungary, and Slovakia
Oct 01, 2013: Medigene announces market launch of Veregen in Taiwan
Sep 10, 2013: Medigene's Drug Veregen receives market approval in Canada
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Warts, H2 2015
Number of Products under Development for Warts - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Warts - Pipeline by 3M Drug Delivery Systems, H2 2015
Warts - Pipeline by Agilvax, Inc., H2 2015
Warts - Pipeline by Biogenomics Limited, H2 2015
Warts - Pipeline by BioMAS Ltd., H2 2015
Warts - Pipeline by Biota Pharmaceuticals, Inc., H2 2015
Warts - Pipeline by EpiPharm AG, H2 2015
Warts - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015
Warts - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2015
Warts - Pipeline by Helix BioPharma Corp., H2 2015
Warts - Pipeline by LEO Pharma A/S, H2 2015
Warts - Pipeline by MediGene AG, H2 2015
Warts - Pipeline by NanoViricides, Inc., H2 2015
Warts - Pipeline by Nielsen Biosciences, Inc., H2 2015
Warts - Pipeline by Novan, Inc., H2 2015
Warts - Pipeline by Novartis AG, H2 2015
Warts - Pipeline by Promius Pharma, LLC, H2 2015
Warts - Pipeline by RXi Pharmaceuticals Corporation, H2 2015
Warts - Pipeline by Tamir Biotechnology, Inc., H2 2015
Warts - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Warts Therapeutics - Recent Pipeline Updates, H2 2015
Warts - Dormant Projects, H2 2015
Warts - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Warts, H2 2015
Number of Products under Development for Warts - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report